Expect Trikafta to Bring Big Changes in Treating Cystic Fibrosis

Trikafta (elexacaftor/tezacaftor/ivacaftor) will be a game changer for treating cystic fibrosis (CF).

It targets a gene mutation found in nearly 90% of CF patients.

Other CF transmembrane conductance regulator (CFTR) modulators...Kalydeco, Orkambi, and Symdeko...target genetic mutations found in fewer than 50% of patients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote